胃肠癌术中放置氟尿嘧啶植入剂的临床观察

目的观察胃肠癌术中放置氟尿嘧啶植入剂的临床观察。方法将100例胃肠道恶性肿瘤病人随机分为观察组和对照组各50例,观察组在手术中放入缓释性5-氟尿嘧啶,对照组单纯手术。观察两组病人术前术后肝肾功能、骨髓抑制、凝血功能情况。结果 ALT、AST、ALB及血常规中WBC与术前比较差异有统计学意义（P〈0.05）;但术后肝功、肾功能、骨髓抑制、凝血功能的各项指标两组间无统计学意义（P〉0.05）。结论胃肠道恶性肿瘤术中植入氟尿嘧啶缓释剂副作用不明显。     

5-氟尿嘧啶缓释剂制备及体外释药性能比较*

背景：5-氟尿嘧啶-聚乳酸-乙醇酸共聚物缓释微球在青光眼滤过术后抑制滤过泡的瘢痕化具有潜在应用价值,但微球制备程序复杂,微球载药量一般较低,且药物突释现象明显。 目的：比较乳化溶剂挥发法制备的5-氟尿嘧啶-聚乳酸-乙醇酸共聚物微球和喷雾成膜法制备的5-氟尿嘧啶-聚乳酸-乙醇酸共聚物缓释膜两种缓释剂的形态、载药量、体外释放规律,以探讨获得缓释效果较佳的5-氟尿嘧啶缓释剂制备方法。 方法：以聚乳酸-乙醇酸共聚物为载体,采用乳化溶剂挥发法制备5-氟尿嘧啶-聚乳酸-乙醇酸共聚物微球;用喷雾成膜法制备5-氟尿嘧啶-聚乳酸-乙醇酸共聚物缓释膜。 结果与结论：用乳化溶剂挥发法制备的微球外观圆整,粒径为(4 447.4±359.8) nm,载药量(8.67±0.37)%,包封率为(86.68± 1.92)%;用喷雾成膜法制备的缓释膜表面光滑平整,质量为(13.76±0.26) mg ,直径为6 mm ,厚度为(0.24±0.005) mm,载药量(23.76±0.37)%,包封率为(95.04±1.36)%。缓释剂制备过程未影响5-氟尿嘧啶的药物性能。微球体外释放突释明显,缓释膜的体外释放平稳持久,释放曲线符合Higuchi方程。结果表明缓释膜制备方法更简单易行,且能明显提高缓释剂的载药量,降低突释现象,同时延长药物的缓释时间。 关键词：聚乳酸-聚乙醇酸;5-氟尿嘧啶;微球;缓释膜;体外释放 doi:10.3969/j.issn.1673-8225.2012.08.022     

强的松龙纳米微球缓释膜的生物安全性

背景：如何用药物去抑制神经修复后瘢痕的生长成为周围神经损伤后功能恢复的关键。课题组以往研究借鉴广泛应用于抗肿瘤药物局部释放的纳米微球缓释技术设计了一种强的松龙纳米微球缓释膜,取得了良好的体外药物缓释效果。 目的：制备强的松龙纳米微球缓释膜,观察该膜的生物相容性及安全性。 方法：采用反胶束乳化溶剂挥发法和球膜结合的方法制备强的松龙纳米微球缓释膜,用细胞毒性实验、溶血实验、急慢性全身毒性实验对药膜的生物安全性进行初步评价。 结果与结论：培养第7天,L929小鼠成纤维细胞相对增殖率为92.6%,证实此膜无细胞毒性;该膜对新鲜的抗凝兔血溶血率为0.59%,无明显的溶血作用;此缓释膜的浸提液腹腔注射小鼠未见明显的生物学行为的异常,对大鼠肝肾功能无明显影响。结果证实,强的松龙纳米微球缓释膜具有良好的生物相容性,安全无毒性。中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程全文链接：     

文拉法辛缓释剂对首发惊恐障碍的疗效及安全性观察

目的观察文拉法辛缓释剂治疗首发惊恐障碍的治疗效果和安全性。方法对37例门诊首发惊恐障碍患者予以文拉法辛缓释剂治疗观察共6周,治疗前后采用汉密尔顿焦虑量表（HAMA,14项）评分观察疗效和国内统一4级疗效评定和比较,以及观察记录不良反应。结果①文拉法辛缓释剂治疗惊恐障碍的临床治愈率和总有效率分别为70.2%和91.9%。文拉法辛缓释剂治疗后的总分在第一周末就已经开始下降,并且差异有显著性（t=11.35,P〈0.05）;②37例患者治疗前后HAMA评分有明显改变,治疗过程中各时段两量表评分比较,差异均有显著性（P〈0.05）,并且文拉法辛缓释剂的疗效随治疗时间的延长而提高;③服药治疗6周后近90%患者的不良反应会自行缓解。结论文拉法辛缓释剂具有起效快,疗效好,安全性高,副作用轻微,依从性好的特点,不失为治疗首发惊恐障碍的首选药物。     

5-氟尿嘧啶载自组装水凝胶纳米粒的制备及体外释放

本实验以乙酰化普鲁兰(PA)为基质材料,采用透析法制备新型自组装水凝胶纳米粒,用以增强5-氟尿嘧啶的药物靶向性及药物选择活性,从而达到降低其毒副作用的目的。用傅立叶红外光谱仪(FT-IR)、动态光散射仪(DLS)和场发射扫描电镜(FE-SEM)对其进行表征。分别测量不同浓度、温度以及储存时间下,PA纳米粒的粒径的变化情况,以研究环境因素的改变对PA纳米粒的粒径及其粒径分布的稳定性影响。使用透析方将5-氟尿嘧啶(5-FU)物理包封于自组装纳米粒中,并模拟人体环境进行了体外释放研究。结果表明,PA纳米粒在不同环境条件下,粒径基本保持恒定,具有良好的稳定性;PA纳米粒的粒径在100nm左右,具有良好的表面球形度且分布均匀;不同环境条件变化下,粒径基本保持恒定,具有良好的稳定性;在18h内,5-FU释放量达70%左右,具有明显的缓释作用。乙酰化程度越低,5-FU的缓释效果越好,但载药量略有下降。PA纳米粒是非常具有应用前景的新型5-FU药物载体。     

纤维素薄膜包衣缓释剂的设计和性能考察

背景：乙基纤维素是常用的不溶性高分子材料,具有良好的成膜性能和机械性能,可用于缓释包衣材料。 目的：制备美斯地浓纤维素薄膜包衣缓释剂,并考察其性能。 方法：以羟丙甲基纤维素为缓释材料,以体外累计释放度为指标,运用单因素考察确定片芯处方,以乙基纤维素为薄膜包衣材料,采用正交实验设计优选出包衣处方,制备美斯地浓纤维素薄膜包衣缓释剂,考察其体外释放性能及对光和热的稳定性能。 结果与结论：通过单因素考察确定以羟丙甲纤维素 K15M作为缓释材料,体积分数95%乙醇溶液为黏合剂制备缓释片片芯,正交实验设计优选出包衣处方为：包衣增重为10%、致孔剂用量为3%、抗黏剂用量为0.1%,纤维素薄膜包衣缓释剂在2,4,8 h的体外累计释放度为(19.52±0.72)%,(42.31±0.61)%,(86.50±0.72)%,具有良好的缓释特征,且对光和热稳定。     

不同类型生物材料的心脏瓣膜应用及安全性评价

背景:组织工程心脏瓣膜是应用工程学和生命科学的原理和方法构建具有生理功能和生物活性的瓣膜替代物,但仍处于动物实验阶段。 目的：总结常用的组织工程心脏瓣膜,对不同类型生物材料的心脏瓣膜应用的安全性进行评价。 方法：以“生物材料,心脏瓣膜,支架材料,综述文献,组织工程”为中文关键词,采用计算机检索2000-01/2010-12相关文章。纳入与生物材料与组织工程心脏瓣膜研究相关的文章;排除重复研究或Meta分析类文章。 结果与结论：共纳入生物材料与组织工程心脏瓣膜研究相关文献20篇。天然支架材料因其优越的生物相容性和三维空间构象,具有其他材料不可比拟的仿生性。合成可降解高分子材料具有良好的可控性和力学性能也备受研究者青睐,而将天然材料和高分子材料融合一体构建的复合支架材料为组织工程心脏瓣膜的研究提供了新的策略和方向,具有广阔的应用前景。     

亲水性丙烯酸酯人工晶状体植入后的生物相容性和并发症

背景：亲水性丙烯酸酯材料的生物相容性良好,在临床得到广泛的应用。但随着亲水性丙烯酸酯人工晶状体临床应用的时间延长,其长期的生物相容性及稳定性问题逐渐显现。目的：讨论亲水性丙烯酸酯人工晶状体植入后的生物相容性及稳定性问题和处理方法。方法：应用计算机检索万方数据库及PubMed数据库2005至2014年与亲水性丙烯酸酯人工晶状体临床应用相关的文献,中文检索词为“亲水性丙烯酸酯,人工晶状体/人工晶体”;英文检索词为“hydrophilic acrylic,intraocular lens”。检索得到618篇中英文文献,根据纳入排除标准选择35篇文献进行总结。结果与结论：亲水性丙烯酸酯人工晶状体具有良好的柔性可折叠性,折叠后能柔软而缓慢的展开,因此植入时所需切口小,手术操作简便时间段,患者损伤小。而且亲水性丙烯酸酯材料的细菌及炎性细胞的黏附性差,所以亲水性丙烯酸酯人工晶状体植入后的感染性眼内炎发生的概率低,但其植入后的后囊混浊发生率高,植入后也存在一定的屈光不正和视觉质量问题,这些问题的解决有赖于人工晶状体材料和设计的不断改进和更新。中国组织工程研究杂志出版内容重点：组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程     

壳聚糖-胶原角膜修复材料的制备及生物相容性

背景：将胶原和壳聚糖按一定比例制成复合膜后,能够降低壳聚糖的正电荷,改善壳聚糖的吸附力,促进细胞的黏附生长、迁移和增殖,增强壳聚糖的生物学性能,成为十分优良的生物材料。 目的：制备壳聚糖-胶原复合膜,观察其与角膜基质层的组织相容性。 方法：制作壳聚糖-胶原复合膜材料。将16只新西兰兔随机分为两组,实验组于右眼角膜基质袋内植入壳聚糖-胶原复合膜,对照组右眼角膜基质袋内植入壳聚糖膜。移植后进行裂隙灯显微镜、前节-光学相干断层成像及组织学观察。 结果与结论：①裂隙灯显微镜：移植后第8周,实验组膜片中央出现降解浸润,皱褶屈曲不明显;对照组膜片全部浸润,皱褶屈曲明显。②前节-光学相干断层成像：移植后第6周,实验组的复合膜边界模糊,密度与正常角膜组织很接近,角膜形态恢复正常。③组织学观察：移植后第8周,实验组膜片表层少量降解,降解材料与角膜基质融合,膜片周围角膜基质有少量炎性细胞浸润;对照组膜片表层降解程度大于实验组,降解物质与角膜基质交织融合,膜片周围角膜基质有较多炎性细胞浸润。表明壳聚糖-胶原复合膜具有可降解性和良好的组织相容性。中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程     

复合表面活性剂处理生物源性骨组织作为骨移植材料的生物安全性研究

目的 应用新型的表面活性剂处理生物源性骨组织,对其进行脱细胞效果及生物安全性评价,以期得到一种更安全、可靠的骨植入材料。方法2种阴离子表面活性剂ABS（十二烷基苯磺酸钠）和AES（脂肪醇聚氧乙烯醚硫酸钠）以及蒸馏水以重量比13：7：80的比例配制复合表面活性剂。以新鲜的牛松质骨为原料,复合表面活性剂脱脂脱细胞的两步法工艺,制备新型生物源性骨植入材料。对其进行组织学和表面超微结构观察,同时对表面活性剂处理的生物源性骨植入材料进行急性全身毒性试验、溶血试验、细胞毒性试验的生物安全性评价。通过骨长期植入试验观察表面活性剂生物源性骨的生物相容性和生物降解性。采用吸光度测量法界定骨材料中表面活性剂的残留量。结果复合表面活性剂生物源性骨颜色呈乳白色,无肉眼可见杂质,组织学及超微结构观察可见骨陷窝内细胞结构消失,骨小管空虚,胶原纤维排列整齐。生物安全性实验表明：按GB／T16886．11—1997急性全身毒性试验合格,溶血试验〈5％,细胞毒性试验0级。复合表面活性剂生物源性骨组织中表面活性剂的残留量低于0．1g／L。骨长期植入实验表明：4周时可见骨组织周围纤维组织生成,骨小梁内有细胞爬入,植入材料与宿主骨融合良好。8周时植入材料部分被机体吸收,24周后被机体完全吸收。结论复合表面活性剂处理的生物源性骨移植材料具有良好的生物相容性和生物降解性,是一种安全、可靠的骨植入材料。     

Injectable hyaluronic acid microhydrogels for controlled release formulation of erythropoietin

An injectable hyaluronic acid (HA) microhydrogel was successfully developed as a novel drug carrier for controlled release formulation of protein drugs. HA hydrogels were prepared by the disulfide bond formation of thiolated HA (HA-SH). EPO was loaded in situ during HA-SH hydrogel preparation using an accelerating agent of sodium tetrathionate. The gelation time was drastically reduced from a day to 30 min when sodium tetrathionate was added for HA-SH hydrogel preparation. In vitro release of EPO in PBS at 37 degrees C showed that EPO was rapidly released for 3 days with an initial burst and then slowly up to 9 days from HA-SH hydrogels. HA-SH microhydrogels were prepared by the reactive spray drying of diluted HA-SH precursor solution. The mean particle size was approximately 2.3 mum and the water content after spray drying was approximately 14%. Ellman's test showed that sodium tetrathionate contributed not only for rapid crosslinking reaction but also for the reduction of residual free thiol content in HA-SH microhydrogels after spray drying. EPO recovery from HA-SH microhydrogels after degradation with hyaluronidase SD was higher than 95%. The released EPO appeared to be intact from the analysis with RP-HPLC. According to in vivo release test of EPO from HA-SH microhydrogels in Sprague Dawley (SD) rats, elevated plasma concentration of EPO higher than 0.1 ng/mL, which is a critical minimal concentration for EPO efficacy, was maintained up to 7 days. There was no adverse effect during and after the in vivo tests.     

文拉法辛缓释剂临床应用专家指导建议

文拉法辛(venlafaxine)是5-羟色胺和去甲肾上腺素再摄取抑制剂,在多个国家作为抑郁症或广泛性焦虑障碍防治指南推荐的一线治疗药物,对躯体化症状也有较好疗效.文拉法辛国内主要使用缓释胶囊等剂型,获批准适应证是各种类型抑郁症和广泛性焦虑障碍.文拉法辛具有相对独特的精神药理、药效、药代动力学特征,使用过程要注意一些事项.为进一步规范其临床应用以发挥最佳疗效,国内相关领域专家结合国内外抑郁症、焦虑障碍诊疗指南、循证医学证据和自身用药经验,撰写本文为临床医生提供科学用药的较全面信息,包括用药技巧、安全性、老年、儿童、孕妇和哺乳期患者等特殊人群中的临床应用等.     

Preparation and drug controlled release of porous octyl-dextran microspheres

In this work, porous octyl-dextran microspheres with excellent properties were prepared by two steps. Firstly, dextran microspheres were synthesized by reversed-phase suspension polymerization. Secondly, octyl-dextran microspheres were prepared by the reaction between dextran microspheres and ethylhexyl glycidyl ether and freezing-drying method. Porous structure of microspheres was formed through the interaction between octyl groups and organic solvents. The structure, morphology, dry density, porosity and equilibrium water content of porous octyl-dextran microspheres were systematically investigated. The octyl content affected the properties of microspheres. The results showed that the dry density of microspheres decreased from 2.35 to 1.21 g/ml, porosity increased from 80.68 to 95.05% with the octyl content increasing from 0.49 to 2.28 mmol/g. Meanwhile, the equilibrium water content presented a peak value (90.18%) when the octyl content was 2.25 mmol/g. Octyl-dextran microspheres showed high capacity. Naturally drug carriers play an important role in drug-delivery systems for their biodegradability, wide raw materials sources and nontoxicity. Doxorubicin (DOX) was used as a drug model to examine the drug-loading capacity of porous octyl-dextran microspheres. The drug-loading efficiency increased with the increase in microspheres/drug ratio, while the encapsulation efficiency decreased. When microspheres/drug mass ratio was 4/1, the drug-loading efficiency and encapsulation efficiency were 10.20 and 51.00%, respectively. The release rate of DOX increased as drug content and porosity increased. In conclusion, porous octyl-dextran microspheres were synthesized successfully and have the potential to serve as an effective delivery system in drug controlled release.     

控制性清创后应用生物辅料及表皮细胞种植修复深Ⅱ度烧伤创面

文题释义：控制性清创：气动/电动取皮刀在深Ⅱ度烧伤创面削痂时可准确控制深度,清创后创面深度均一,在清除坏死真皮层时本着“宁浅勿深”的原则,尽可能不损伤正常真皮组织及皮肤附件,改善瘀滞带血运,从而促进深Ⅱ度烧伤愈合。尽管该技术在临床已经逐步推广使用,但目前尚无科学设计、严格对照的临床试验研究,更缺乏远期的效果观察,也没有统一的操作规范和技术应用标准,其治疗是否真正优于传统换药尚需大规模随机对照临床研究证实。 表皮细胞种植技术：是一个可迅速采集自身表皮细胞并将其用于治疗自身创面的综合技术,其治疗面积可达供皮区的40-80倍,在深Ⅱ度烧伤创面削痂保留正常真皮组织的创面上实施表皮细胞种植技术有望加速创面愈合过程,该技术特点在于以微小的供皮区为代价,加速40-80倍的烧伤创面愈合。该技术在国外应用较广泛,由于价格昂贵,在国内使用尚处于起步阶段。 背景：针对目前深Ⅱ度烧伤创面治疗修复方法多样,效果不一,缺乏规范与统一,有必要开发的新技术。 目的：观察控制性清创与传统型方法对深Ⅱ度烧伤创面的治疗效果。 方法：2015年6月至2018年6月共入选80例深Ⅱ度烧伤患者,分成阳性对照组和控制性清创组进行研究,每组40例。阳性对照组外涂邦尔康烧伤抑菌霜,油纱覆盖加压包扎,分别于伤后第3,6,9,12天换药;控制性清创组按创面制备要求,制备表皮细胞悬液,喷洒至创面,用Recell套装自带保护膜覆盖创面,术后第3天打开保持干燥,随后观察术后第6,9,12天创面情况。该研究得到空军军医大学西京医院伦理委员会的批准,所有患者均自愿参加,知情并签署知情同意书。采用在线登记患者信息,并根据随机(软件在线提供)分组治疗方案进行相应治疗准备。 结果与结论：控制性清创组创面细菌含量、创面疼痛评分、创面感染评分、促炎性因子水平明显低于阳性对照组,差异有显著性意义(P < 0.05),且均未发生不良反应。该结果表明,表皮细胞种植技术结合控制性清创用于深Ⅱ度创面的治疗方案具有促进创面愈合、减轻感染、降低患者痛苦的作用,效果显著。 ORCID: 0000-0002-0367-0494(石雪芹) 中国组织工程研究杂志出版内容重点：组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程     

Preparation of chitosan/ethylcellulose complex microcapsule and its application in controlled release of vitamin D2

A system which consists of chitosan (CS) microcores entrapped within enteric polymer is investigated. Vitamin D2 (VD2) used as a model drug, was efficiently entrapped in CS microcores using spray drying and was microencapsulated by coating of ethylcellulose. The morphology and release properties of microcapsules were tested. The factors which influenced the preparation, including molecular weight of CS, concentration of CS solution, concentration of acetic acid and loading of VD2, were discussed. The results of release in vitro showed that the microcapsules could realize sustained release in intestine juice.     

Biostability and biological performance of a PDMS-based polyurethane for controlled drug release

Polymers have been used to deliver therapeutic agents in a range of medical devices with drug eluting stents being the most widespread current application. Although polymers enable controlled release of a therapeutic agent, the polymeric surface has been reported to provide suboptimal biocompatibility and haemocompatibility and it has been suggested that currently used polymers may be at least partly responsible for the late adverse events observed in intravascular stent systems. In this study, the biostability and biological performance of a siloxane-based polyurethane elastomer (E2A) demonstrating excellent long-term biostability in the unloaded state was investigated following incorporation of a therapeutic agent. After implantation in an ovine model for 6 months, samples were assessed using SEM and ATR-FTIR to determine changes in the surface chemical structure and morphology of the materials and tensile testing was used to examine changes in bulk characteristics. Biological response was assessed using in vitro cytotoxicity testing and histological analysis. Results indicated that incorporation of 25 mg/g dexamethasone acetate (DexA) into the siloxane-based polyurethane resulted in no significant difference in the biostability and biocompatibility of the material. Some level of cytotoxic potential was exhibited which was believed to result from residual DexA leaching from samples during the extraction process. These findings suggest that E2A is a potential candidate for a delivery vehicle of therapeutic agents in implantable drug delivery applications.     

Biodegradable dextran-polylactide hydrogel network and its controlled release of albumin

The objective of this paper was to study the release of bovine serum albumin (BSA) from a series of biodegradable hydrogels having a wide range of hydrophilicity to hydrophobicity, swelling, and biodegradation properties. BSA was incorporated into a series of biodegradable hydrogels made from a dextran derivative of allyl isocyanate (dex-AI, as the hydrophilic constituent) and poly(DL-lactic acid) diacrylate macromer (PDLLAM, as the hydrophobic constituent). The release kinetics of BSA from these dex-AI/PDLLAM hydrogels was studied. Laser confocal scanning microscopy was used to investigate the morphological change of the hydrogels, as well as BSA distribution in the hydrogels, as a function of dex-AI to PDLLAM composition ratio and incubation time. We found that the incorporation of PDLLAM into dex-AI reduced the initial burst release of BSA due to its more homogeneous distribution in the hydrogels. As the PDLLAM component increased, the rate of formation of a loose three-dimensional (3D) network structure increased; consequently, the sustained rate and extent of BSA release increased. Both release index and diffusion coefficient (from release kinetics data) increased as the PDLLAM component increased in the hydrogels. The data suggest that the release of BSA was controlled by both diffusion of BSA through swelling of the hydrophilic phase during an early stage, and degradation of the hydrophobic phase during a late stage, and also that the magnitude of diffusion versus degradation controlled release is dependent on composition ratio and immersion time.     

应用生物可降解材料玉米醇溶蛋白制备胃肠道生物黏附控释片

背景：胃肠道生物黏附控释制剂能延长药物制剂在胃肠道的停留时间,提高药物的生物利用度。 目的：制备5-氟尿嘧啶胃肠道生物黏附控释片。 方法：利用生物可降解性玉米醇溶蛋白为骨架材料和黏附材料,氟尿嘧啶为模型药,制备氟尿嘧啶胃肠道黏附控释片。对片芯工艺进行正交设计,优化包衣液的选择,观察生物黏附缓释片的体外黏附力及体内外相关性。 结果与结论：5-氟尿嘧啶玉米醇溶蛋白生物黏附片体外释放10 h内均符合零级释放特征,片剂具有较好的体外黏附力,且在2~8 h 内体内血药浓度较为平稳,没有明显峰谷现象,体内外释放吸收具有良好的相关性。     

Preparation and characterization of magnetic thermosensitive fluorouracil micelles

In this study, we synthesized P(NIPAM-co-DMAM)-b-PLA polymers with free radical polymerization and ring-opening addition polymerization, and immediately assembled ‘dextran magnetic layered double hydroxide fluorouracil’ (DMF) magnetic particles into the core of the amphiphilic polymer micelles with synchronous hydration and dialysis, to generate a magnetic thermosensitive fluorouracil drug delivery system. The basic properties of the micelle particles, such as the core–shell-type structure, size, and zeta potential, were studied with ¹H-NMR, FTIR, TEM, TGA, laser nanoparticle size analysis, and other characterization techniques. The thermosensitivity of the micelles was investigated by measuring parameters such as the lower critical solution temperature (LCST) and the relationship between the particle size variation and temperature. The drug release curves for the micelles at different temperatures were constructed with a dialysis method. The LCST of the triblock polymers was 42 °C. The particle sizes of the blank micelles and DMF-loaded micelles were 493.6 ± 1.8 nm and 464.9 ± 4.1 nm, respectively, at 25 °C. When the temperature was higher than LSCT, a contraction phase change in the micelle structure occurred, a significant characteristic of the core–shell-type structure, and reversible phase transition phenomena. The release behavior of the drug-loaded micelles showed obvious variations with temperature. Therefore, the magnetic thermosensitive fluorouracil drug delivery system has a good magnetic response and excellent temperature controlled release characteristics, so it can be used as a drug delivery system in magnetically and thermally targeted chemotherapy for tumors.